Antitrust & competition stories

Aug 3, 2026

Sandoz agrees to $450 million settlement with 43 US states over generic drug price-fixing allegations

Swiss generic drugmaker Sandoz has reached a settlement agreement to pay $450 million to 43 US states and territories to resolve antitrust litigation alleging anti-competitive conduct and price manipulation in the generic medicines market. The settlement includes no admission of wrongdoing and will not affect the company's financial guidance.

Aug 3, 2026·9 sources

Jun 26, 2026

European Commission Opens Antitrust Investigation Into Sanofi's Flu Vaccine Marketing Practices

The European Commission launched an antitrust probe into Sanofi for allegedly disparaging a rival's flu vaccine in its marketing campaigns, potentially violating competition rules.

Jun 26, 2026·3 sources

Apr 23, 2026

Warner Bros Shareholders Approve $110 Billion Paramount Merger

Warner Bros Discovery shareholders voted to approve the company's proposed $110 billion merger with Paramount Skydance, one of the largest media consolidations in history. The deal now faces regulatory scrutiny in Washington and London.

Apr 23, 2026·5 sources

Top claims

▪Sandoz Inc. will pay an additional $50 million to states that settled related generic drug claims earlier.
▪The settlements do not affect Sandoz Inc.'s full-year 2026 financial guidance or its mid-term outlook.
▪Sandoz Inc. entered into a separate $28.5 million settlement agreement with a putative class of indirect reseller plaintiffs, including retail pharmacies, clinics, and hospitals.

Subtopics

European Union Regulatory enforcement Warner Bros. Discovery Media industry consolidation Corporate governance

Related timelines

Antitrust & competition stories

Sandoz agrees to $450 million settlement with 43 US states over generic drug price-fixing allegations

European Commission Opens Antitrust Investigation Into Sanofi's Flu Vaccine Marketing Practices

Warner Bros Shareholders Approve $110 Billion Paramount Merger

Related timelines

Iran War

US Congress

Venture capital funding

Strait of Hormuz blockage

Trump administration